The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels
Yıl: 2019 Cilt: 28 Sayı: 1 Sayfa Aralığı: 8 - 14 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2018.00710 İndeks Tarihi: 17-07-2019
The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels
Öz: Objectives: To investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) in detection of recurrence in ovarian cancer patients with increased CA-125 levels. Methods: Fifty-two patients (30-80 years old, mean: 58.5±10.6 years) who had been histopathologically diagnosed with ovarian cancer, underwent 18F-FDG PET/CT imaging for re-staging due to elevation of CA-125 levels were included in this retrospective study. 18F-FDG PET/CT findings were compared with histopathological, radiological and clinical follow-up results. Results: CA-125 levels ranged between 35.2-2740 U/mL (N: 0-35 U/mL). Recurrent disease was detected in 45 of 52 patients on PET/CT imaging. There were three false negative and one false positive result. In addition to abdominal and pelvic lesions, 14 distant metastatic lesions (brain, lung, liver and bone metastasis) were identified correctly on PET/CT imaging. Sensitivity, specificity, positive and negative predictive value and accuracy of 18F-FDG PET/CT were calculated as 94%, 75%, 98%, 50% and 96%, respectively. Conclusion: 18F-FDG PET/CT is a useful imaging method that can be used in detection of ovarian cancer recurrence in patients with elevated CA-125 levels. Since this modality offers whole body imaging, distant metastases could be detected in addition to abdominal and pelvic lesions thus contributing to patient management.
Anahtar Kelime: Konular:
CA-125 Düzeylerinde Artış Olan Over Kanserli Hastalarda Rekürrens Saptamada 18F-FDG PET/BT’nin Rolü
Öz: Amaç: Bu çalışmanın amacı, serum CA-125 düzeylerinde artış olan over kanserli hastalarda rekürrens saptamada 18F-FDG pozitron emisyon tomografi/bilgisayarlı tomografinin (PET/BT) rolünü araştırmaktır. Yöntem: Bu retrospektif çalışmaya histopatolojik olarak over kanseri tanısı almış, CA-125 düzeylerinde artış nedeniyle yeniden evreleme amacıyla 18F-FDG PET/BT yapılan 52 hasta (30-80 yaş, ortalama: 58,5±10,6 yaş) dahil edildi. 18F-FDG PET/BT bulguları histopatolojik bulgular veya radyolojik ve klinik izlem sonuçlarıyla karşılaştırıldı. Bulgular: CA-125 düzeyleri 35,2-2740 U/mL (N: 0-35 U/mL) aralığındaydı. PET/BT görüntülerinde rekürren hastalık 52 hastanın 45’inde gösterildi. Üç yanlış negatif, bir yanlış pozitif sonuç elde edildi. Abdominal ve pelvik lezyonlara ilave olarak 14 uzak metastaz (beyin, akciğer, karaciğer ve kemik metastazı) PET/BT ile doğru olarak gösterildi. Duyarlılık, özgüllük, pozitif ve negatif öngörü değeri ve doğruluk sırasıyla %94, %75, %98, %50 ve %96 idi. Sonuç: 18F-FDG PET/BT, serum CA-125 düzeylerinde artış olan over kanserli hastalarda rekürrens saptamada kullanılabilecek yararlı bir yöntemdir. Tüm vücut görüntüleme yöntemi olması nedeniyle abdominal ve pelvik lezyonların yanında uzak metastazları da saptayarak bu hastaların izlemine katkıda bulunabilir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:25192529.
- Berek JS, Tropé C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999;10(Suppl 1):3-7.
- Pignata S, Cecere SC, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol 2017;28(Suppl 8):vii51-vii56.
- Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics. 2011;31:569-583.
- Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR Jr, Bast RC Jr. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986;155:56-60.
- Kruse V, Cocquyt V, Borms M, Maes A, Van de Wiele C. Serum tumor markers and PET/CT imaging for tumor recurrence detection. Ann Nucl Med 2013;27:97-104.
- Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004;241:209-223.
- von Georgi R, Schubert K, Grant P, Münstedt K. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2004;1142:228-233.
- Meyer T, Rustin GJ. Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;83:1535-1538.
- Kim HJ, Kim JK, Cho KS. CT features of serous surface papillary carcinoma of the ovary. ARJ Am J Roentgenol 2004;183:1721-1724.
- . Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009;112:462-468.
- Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009;71:164-174.
- Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 2007;316:868-875.
- Cho SM, Ha HK, Byun JY, Lee JM, Kim CJ, Nam-Koong SE, Lee JM. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol 2002;179:391-395.
- Fagotti A, Fanfani F, Rossitto C, Lorusso D, De Gaetano AM, Giordano A, Vizzielli G, Scambia G. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology 2008;75:152-158.
- Sari O, Kaya B, Kara PO, Gedik GK, Celik C, Ozbek O, Serdengecti M. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases. Rev Esp Med Nucl Imagen Mol 2012;31:3-8.
- Risum S, Høgdall C, Markova E, Berthelsen AK, Loft A, Jensen F, Høgdall E, Roed H, Engelholm SA. Influence of 2-(18F) fluoro2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009;19:600-604.
- Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 2007;171: 21-31.
- Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, Kang KW, Lee JS, Jeong JY, Park SY. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/ computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 2006;106:914-922.
- Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, Vigano R, Picchio M, Taccagni G, Maschio AD, Fazio F. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233:433-440.
- Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rev Esp Med Nucl Imagen Mol 2014;331:22-27.
- Yuan Y, Gu ZX, Tao XF, Liu SY. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a metaanalysis. Eur J Radiol 2012;815:1002-1006.
- Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271-276.
| APA | CENGİZ A, Koç Z, ÖZCAN KARA P, YÜREKLİ Y (2019). The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. , 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| Chicago | CENGİZ ARZU,Koç Zehra Pınar,ÖZCAN KARA Pelin,YÜREKLİ Yakup The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. (2019): 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| MLA | CENGİZ ARZU,Koç Zehra Pınar,ÖZCAN KARA Pelin,YÜREKLİ Yakup The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. , 2019, ss.8 - 14. 10.4274/mirt.galenos.2018.00710 |
| AMA | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. . 2019; 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| Vancouver | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. . 2019; 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| IEEE | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y "The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels." , ss.8 - 14, 2019. 10.4274/mirt.galenos.2018.00710 |
| ISNAD | CENGİZ, ARZU vd. "The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels". (2019), 8-14. https://doi.org/10.4274/mirt.galenos.2018.00710 |
| APA | CENGİZ A, Koç Z, ÖZCAN KARA P, YÜREKLİ Y (2019). The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. Molecular Imaging and Radionuclide Therapy, 28(1), 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| Chicago | CENGİZ ARZU,Koç Zehra Pınar,ÖZCAN KARA Pelin,YÜREKLİ Yakup The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. Molecular Imaging and Radionuclide Therapy 28, no.1 (2019): 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| MLA | CENGİZ ARZU,Koç Zehra Pınar,ÖZCAN KARA Pelin,YÜREKLİ Yakup The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. Molecular Imaging and Radionuclide Therapy, vol.28, no.1, 2019, ss.8 - 14. 10.4274/mirt.galenos.2018.00710 |
| AMA | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. Molecular Imaging and Radionuclide Therapy. 2019; 28(1): 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| Vancouver | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels. Molecular Imaging and Radionuclide Therapy. 2019; 28(1): 8 - 14. 10.4274/mirt.galenos.2018.00710 |
| IEEE | CENGİZ A,Koç Z,ÖZCAN KARA P,YÜREKLİ Y "The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels." Molecular Imaging and Radionuclide Therapy, 28, ss.8 - 14, 2019. 10.4274/mirt.galenos.2018.00710 |
| ISNAD | CENGİZ, ARZU vd. "The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels". Molecular Imaging and Radionuclide Therapy 28/1 (2019), 8-14. https://doi.org/10.4274/mirt.galenos.2018.00710 |
